一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Mifamurtide

Mifamurtide Struktur
83461-56-7
CAS-Nr.
83461-56-7
Englisch Name:
Mifamurtide
Synonyma:
MIFAMURTIDE;MTP-PE;muramyl tripeptide phosphatidylethanolamine;CGP 19835;MLV 19835;MTP-cephalin;L-MTP-PE. MTP-PE;CGP 19835A Lipid;Medchemexpress(MTP-PE);Mifamurtide (CGP-19835)
CBNumber:
CB11249151
Summenformel:
C59H109N6O19P
Molgewicht:
1237.52
MOL-Datei:
83461-56-7.mol

Mifamurtide Eigenschaften

Dichte
1.152
storage temp. 
-20°C
L?slichkeit
water: soluble2mg/mL, clear (warmed)
Aggregatzustand
powder
pka
1.39±0.50(Predicted)
Farbe
white to beige
Wasserl?slichkeit
water: 2mg/mL, clear (warmed)
InChIKey
ZVLWUMPAHCEZAW-HYGHKABSNA-N
CAS Datenbank
83461-56-7

Sicherheit

WGK Germany  3
Speicherklasse 11 - Combustible Solids

Mifamurtide Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Osteosarcoma.

Mechanism of action

Being a phospholipid, mifamurtide accumulates in the lipid bilayer of the liposomes upon infusion. After application of the liposomal infusion, the drug is cleared from the plasma within minutes. However, it is concentrated in lung, liver, spleen, nasopharynx and thyroid, and the terminal half-life is 18 hours, which is longer than the natural substance.

Clinical Use

Mifamurtide is an anticancer agent for the treatment of osteosarcoma, the most common primary malignancy of bone tissue mainly affecting children and adolescents. The drug was invented by Ciba-Geigy (now Novartis) in the early 1980s and the agent was subsequently licensed to Jenner Biotherapies in the 1990s. IDM Pharma bought the rights to the drug from Jenner in April 2003.In March 2009, mifamurtide was approved in the 27 European Union member states plus Iceland, Liechtenstein and Norway via a centralized marketing authorization. After the approval, IDM Pharma was acquired by Takeda, which began launching mifamurtide, as Mepact ®, in February 2010. Mifamurtide, a fully synthetic lipophilic derivative of muramyl dipeptide (MDP), is muramyl tripeptide phosphatidylethanolamine (MTP-PE), which is formulated as a liposomal infusion.

Nebenwirkungen

Mifamurtide is generally well tolerated; adverse events attributed to its administration include chills, fever, headache, nausea, and myalgias[1].

Mifamurtide Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Mifamurtide Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 76)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971
deasea125996@gmail.com China 2472 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-87569262 +86-15003564040
1056@dideu.com China 3972 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21585 55
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29812 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19936 58
TargetMol Chemicals Inc.
+1-781-999-5354; +17819995354
marketing@targetmol.com United States 32466 58
Shanghai Acmec Biochemical Technology Co., Ltd.
+86-18621343501; +undefined18621343501
product@acmec-e.com China 33324 58
SHANGHAI KEAN TECHNOLOGY CO., LTD.
+8613817748580
cooperation@kean-chem.com China 40066 58
Chongqing Chemdad Co., Ltd
+86-023-6139-8061 +86-86-13650506873
sales@chemdad.com China 39927 58
LGM Pharma 1-(800)-881-8210
inquiries@lgmpharma.com United States 2123 70

83461-56-7()Verwandte Suche:


  • N-Acetylmuramyl-alanyl-isoglutaminyl-alanyl-sn-glycero-3-phosphoethano lamine
  • N-(N-Acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-L-alaninamide
  • CGP 19835
  • L-MTP-PE. MTP-PE
  • MLV 19835
  • MTP-cephalin
  • N-(N-Acetylmuramoyl)-L-alanyl-D-α-glutaminyl-N-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-L-alaninamide
  • muramyl tripeptide phosphatidylethanolamine liposome
  • L-Alaninamide, N-(N-acetylmuramoyl)-L-alanyl-D-α-glutaminyl-N-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-
  • N-Acetylmuramyl-alanyl-isoglutaminyl-alanyl-sn-glycero-3-phosphoethano lamine USP/EP/BP
  • CGP 19835A LIPID;MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE LIPOSOME;L-MTP-PE;CGP-19835;MTP-PE;MTP-CEPHALIN;CGP19835;L-MTP-PE;MLV19835
  • CGP 19835A Lipid
  • Mifamurtide (CGP-19835)
  • MIFAMURTIDE
  • MTP-PE
  • Medchemexpress(MTP-PE)
  • muramyl tripeptide phosphatidylethanolamine
  • 83461-56-7
Copyright 2019 ? ChemicalBook. All rights reserved
朝阳区| 益阳市| 淮阳县| 蒙自县| 永仁县| 桃园市| 东城区| 八宿县| 务川| 扶余县| 收藏| 甘孜县| 石门县| 根河市| 寿宁县| 迭部县| 金阳县| 衡水市| 图木舒克市| 北票市| 高陵县| 清丰县| 双江| 图木舒克市| 云浮市| 来凤县| 延庆县| 孝感市| 吉隆县| 保定市| 邵武市| 海南省| 三明市| 融水| 即墨市| 阳春市| 梁山县| 井冈山市| 文山县| 金昌市| 岑巩县|